Fluticasone Furoate; Vilanterol Trifenatate Patent Expiration
Fluticasone Furoate; Vilanterol Trifenatate is used for the long-term maintenance treatment of airflow obstruction in patients with COPD and asthma, including chronic bronchitis and emphysema, to reduce exacerbations. It was first introduced by Glaxo Group Ltd England Dba Glaxosmithkline
Fluticasone Furoate; Vilanterol Trifenatate Patents
Given below is the list of patents protecting Fluticasone Furoate; Vilanterol Trifenatate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Breo Ellipta | US11116721 | Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol | Feb 26, 2029 | Glaxo Grp Ltd |
| Breo Ellipta |
US11116721 (Pediatric) | Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol | Aug 26, 2029 | Glaxo Grp Ltd |
| Breo Ellipta | US5873360 | Inhalation device |
Feb 23, 2016
(Expired) | Glaxo Grp Ltd |
| Breo Ellipta | US6537983 | Anti-inflammatory androstane derivatives |
Aug 03, 2021
(Expired) | Glaxo Grp Ltd |
| Breo Ellipta | US6759398 | Anti-inflammatory androstane derivative |
Aug 03, 2021
(Expired) | Glaxo Grp Ltd |
| Breo Ellipta | US6878698 | Anti-inflammatory androstane derivatives |
Aug 03, 2021
(Expired) | Glaxo Grp Ltd |
| Breo Ellipta | US7101866 | Anti-inflammatory androstane derivative |
Aug 03, 2021
(Expired) | Glaxo Grp Ltd |
| Breo Ellipta | US7101866 | Anti-inflammatory androstane derivative |
Aug 03, 2021
(Expired) | Glaxo Grp Ltd |
| Breo Ellipta | US7361787 | Phenethanolamine derivatives for treatment of respiratory diseases |
Mar 23, 2023
(Expired) | Glaxo Grp Ltd |
| Breo Ellipta | US7439393 | Phenethanolamine derivatives for treatment of respiratory diseases | May 21, 2025 | Glaxo Grp Ltd |
| Breo Ellipta |
US7439393 (Pediatric) | Phenethanolamine derivatives for treatment of respiratory diseases | Nov 21, 2025 | Glaxo Grp Ltd |
| Breo Ellipta | US7629335 | Anti-inflammatory androstane derivative |
Aug 03, 2021
(Expired) | Glaxo Grp Ltd |
| Breo Ellipta | US7776895 | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases |
Sep 11, 2022
(Expired) | Glaxo Grp Ltd |
| Breo Ellipta | US8113199 | Counter for use with a medicament dispenser | Oct 23, 2027 | Glaxo Grp Ltd |
| Breo Ellipta |
US8113199 (Pediatric) | Counter for use with a medicament dispenser | Apr 23, 2028 | Glaxo Grp Ltd |
| Breo Ellipta | US8161968 | Medicament dispenser | Feb 05, 2028 | Glaxo Grp Ltd |
| Breo Ellipta |
US8161968 (Pediatric) | Medicament dispenser | Aug 05, 2028 | Glaxo Grp Ltd |
| Breo Ellipta | US8511304 | Medicament dispenser | Jun 14, 2027 | Glaxo Grp Ltd |
| Breo Ellipta |
US8511304 (Pediatric) | Medicament dispenser | Dec 14, 2027 | Glaxo Grp Ltd |
| Breo Ellipta | US8534281 | Manifold for use in medicament dispenser | Mar 08, 2030 | Glaxo Grp Ltd |
| Breo Ellipta |
US8534281 (Pediatric) | Manifold for use in medicament dispenser | Sep 08, 2030 | Glaxo Grp Ltd |
| Breo Ellipta | US8746242 | Medicament dispenser | Oct 11, 2030 | Glaxo Grp Ltd |
| Breo Ellipta |
US8746242 (Pediatric) | Medicament dispenser | Apr 11, 2031 | Glaxo Grp Ltd |
| Breo Ellipta | US9333310 | Medicament dispenser | Oct 02, 2027 | Glaxo Grp Ltd |
| Breo Ellipta |
US9333310 (Pediatric) | Medicament dispenser | Apr 02, 2028 | Glaxo Grp Ltd |
| Breo Ellipta | USRE44874 | Phenethanolamine derivatives for treatment of respiratory diseases |
Mar 23, 2023
(Expired) | Glaxo Grp Ltd |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳